The Patent Finder

Jenrin Discovery, Inc.

Also on record
Records under this name other than the patents Jenrin Discovery, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 10 patents it holds.

Back to Jenrin Discovery, Inc.

PatentTitleStatus Expires Confidence
US 9,987,253Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
Lapsed on the fee record
Ended Jun 5, 2026 · From the USPTO record
Lapsed on the fee recordEnded Jun 5, 2026From the USPTO record
US 8,680,131Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
Lapsed on the fee record
Ended Mar 25, 2026 · From the USPTO record
Lapsed on the fee recordEnded Mar 25, 2026From the USPTO record
US 11,179,370Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
Lapsed on the fee record
Ended Nov 23, 2025 · From the USPTO record
Lapsed on the fee recordEnded Nov 23, 2025From the USPTO record
US 9,517,228Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
Lapsed on the fee record
Ended Dec 13, 2024 · From the USPTO record
Lapsed on the fee recordEnded Dec 13, 2024From the USPTO record
US 10,617,673Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
Lapsed on the fee record
Ended Apr 14, 2024 · From the USPTO record
Lapsed on the fee recordEnded Apr 14, 2024From the USPTO record
US 8,088,809Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
Lapsed on the fee record
Ended Jan 3, 2024 · From the USPTO record
Lapsed on the fee recordEnded Jan 3, 2024From the USPTO record
US 9,133,127Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
Lapsed on the fee record
Ended Sep 15, 2023 · From the USPTO record
Lapsed on the fee recordEnded Sep 15, 2023From the USPTO record
US 8,716,2654-quinolinemethanols as anti-malarial agents
Lapsed on the fee record
Ended May 6, 2018 · From the USPTO record
Lapsed on the fee recordEnded May 6, 2018From the USPTO record
US 7,687,481Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
Lapsed on the fee record
Ended Mar 30, 2018 · From the USPTO record
Lapsed on the fee recordEnded Mar 30, 2018From the USPTO record
US 7,649,115MAO-B inhibitors useful for treating obesity
Lapsed on the fee record
Ended Jan 19, 2018 · From the USPTO record
Lapsed on the fee recordEnded Jan 19, 2018From the USPTO record
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited